Dr. Petrylak on Combinations with Pembrolizumab in Urothelial Carcinoma

Daniel P. Petrylak, MD
Published: Wednesday, Jul 12, 2017



Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.

There are many combinations that are currently being investigated, explains Petrylak. There is a combination of ramucirumab (Cyramza) plus pembrolizumab. Additionally, there is a study trying to determine if using anti-angiogenesis agents reverses the resistance that is seen with immunotherapy.

There are studies that are combining agents such as OX40 agonists, states Petrylak. Other combinations are currently being studied, as well as upfront chemotherapy and immunotherapy.



Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.

There are many combinations that are currently being investigated, explains Petrylak. There is a combination of ramucirumab (Cyramza) plus pembrolizumab. Additionally, there is a study trying to determine if using anti-angiogenesis agents reverses the resistance that is seen with immunotherapy.

There are studies that are combining agents such as OX40 agonists, states Petrylak. Other combinations are currently being studied, as well as upfront chemotherapy and immunotherapy.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x